Sangamo Therapeutics (NASDAQ:SGMO) Earns “Buy” Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $5.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 224.68% from the company’s previous close.

Separately, StockNews.com initiated coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $2.67.

Sangamo Therapeutics Trading Up 27.3 %

Shares of NASDAQ SGMO opened at $1.54 on Tuesday. The firm has a market capitalization of $320.66 million, a P/E ratio of -1.12 and a beta of 1.23. The firm’s 50-day moving average price is $0.86 and its 200-day moving average price is $0.66. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.77.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $11.40 million. Equities research analysts forecast that Sangamo Therapeutics will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System boosted its holdings in Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics during the second quarter worth about $67,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics in the 2nd quarter worth about $89,000. Vontobel Holding Ltd. increased its stake in Sangamo Therapeutics by 412.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 241,440 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 1st quarter worth approximately $331,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.